Connect with us

Health

WHO Approves Two New Medicines For Ebola Treatment

Published

on

The World Health Organisation (WHO) has recommended two medicines for the treatment of Ebola virus disease, following successes in clinical trials.

In its new guidelines for Ebola, the global public health body said monoclonal antibodies mAb114 (known as Ansuvimab or Ebanga) and REGN-EB3 (Inmazeb) have demonstrated clear benefits for people who have tested positive for Ebola.

This includes older persons, pregnant and breastfeeding women, children, and newborns whose mothers were confirmed to have Ebola within the first seven days after birth.

The clinical trials were conducted during Ebola outbreaks.

WHO said the largest trial was carried out in the Democratic Republic of the Congo, demonstrating that the highest level of scientific rigour can be applied even during Ebola outbreaks in difficult contexts.

The UN agency also provided recommendations regarding therapeutics that should not be used as treatments, which include ZMapp and remdesivir.

The new guidance, published simultaneously in English and French, will support healthcare providers caring for Ebola patients and policymakers involved in outbreak preparedness and response.

The clinical trials were conducted during Ebola outbreaks.

WHO said the largest trial was carried out in the Democratic Republic of the Congo, demonstrating that the highest level of scientific rigour can be applied even during Ebola outbreaks in difficult contexts.

The UN agency also provided recommendations regarding therapeutics that should not be used as treatments, which include ZMapp and remdesivir.

The new guidance, published simultaneously in English and French, will support healthcare providers caring for Ebola patients and policymakers involved in outbreak preparedness and response.

It complements clinical care guidance that outlines the optimised supportive care that Ebola patients should receive – from the relevant tests to administer to managing pain, nutrition and co-infections, and other approaches that put patients on the best path to recovery.

“This therapeutic guide is a critical tool to fight Ebola,” said Dr Richard Kojan, co-chair of the expert group selected by WHO to develop the guidelines, and president of ALIMA, The Alliance for International Medical Action.

“As with other infectious diseases, timeliness is key, and people should not hesitate to consult health workers as quickly as possible to ensure they receive the best care possible.”

Fellow co-chair Robert Fowler from the University of Toronto in Canada noted that Ebola used to be perceived as “a near certain killer,” but advances in care and therapeutics over the past decade have revolutionised the treatment of the disease.

“Provision of best supportive medical care to patients, combined with monoclonal antibody treatment – MAb114 or REGN-EB3 – now leads to recovery for the vast majority of people,” he added.

As access to these treatments remains challenging, especially in poor areas, WHO said they should be available where they are most needed, namely in locations where active Ebola outbreaks are occurring or where the threat of an outbreak is high or very likely.

“We have seen incredible advances in both the quality and safety of clinical care during Ebola outbreaks,” said Janet Diaz, lead of the clinical management unit in WHO’s Health Emergencies programme.”

(NAN)

Continue Reading
Advertisement
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Health

COVID-19: China Announces New Death, New Cases

Published

on

China announced its first new death from COVID-19 in nearly half a year as strict new measures are imposed in Beijing and across the country to ward against new outbreaks.

Fidel Info reports that The death of the 87-year-old Beijing man was the first reported by the National Health Commission since May 26, bringing the total death toll to 5,227. The previous death was reported in Shanghai, which underwent a major springtime surge in cases.

China, today, announced 24,215 new cases detected over the previous 24 hours, the vast majority of them asymptomatic.

While China has an overall vaccination rate of more than 92% having received at least one dose, that number is considerably lower among the elderly — particularly those over age 80 — where it falls to just 65%. The commission did not give details on the vaccination status of the latest deceased.

That vulnerability is considered one reason why China has mostly kept its borders closed and is sticking with its rigid “zero-COVID” policy that seeks to wipe out infections through lockdowns, quarantines, case tracing and mass testing, despite the impact on normal life and the economy and rising public anger at the authorities.

China says its tough approach has paid off in much lower numbers of cases and deaths than in other countries, such as the U.S.

Continue Reading

Health

JUST IN: Ogun Govt Records Four Fresh Cases Of Monkeypox

Published

on

The Ogun State government has confirmed four new cases of monkeypox, bringing the total cases recorded in the state to seven

Health commissioner Tomi Coker confirmed the development in a statement on Friday in Abeokuta.

Ms Coker stated that two cases were discovered in Ota, within Ado-Odo/Ota Local Government Area, while Abeokuta North and Abeokuta South recorded one case each.

He added that the Disease Surveillance and Notification Officers (DSNOs) in the affected local government areas had carried out line-listing and contact tracing, adding that the patients are already on prescribed medications.

The commissioner advised residents to avoid direct contact with body fluid, or sore of an infected live or dead animal, persons or contaminated items.

She stressed the need for regular hand washing with soap and water, especially after visiting or caring for a sick person.

Ms Coker urged residents to remain calm and assured that necessary measures are being put in place to curb the spread of the disease.

(NAN)

Continue Reading

Health

JUST IN: NCDC Confirms New Cases Of Lassa Fever

Published

on

 

The Nigeria Centre for Disease Control (NCDC) has confirmed 13 new cases of Lassa fever in seven days from five states, Ondo, Edo, Kogi, Ebonyi, and Imo.

The NCDC in its epidemiological report made available to the News Agency of Nigeria(NAN) on Monday, said that, since the beginning of 2022, 70 per cent of infections had come from three states: Ondo (31 per cent), Edo (26 per cent), and Bauchi (13 per cent).

NAN reports that Lassa fever is an acute viral haemorrhagic illness caused by the Lassa virus. People usually become infected with the Lassa virus through exposure to food or household items contaminated with urine or faeces of infected rats – present in several West African countries where the disease is endemic.

The virus could also be spread through infected bodily fluids.

The public health agency said that the country had recorded 165 deaths in 17 states.

The agency said, ”In week 31 (Aug. 1 to 7), the number of new confirmed cases increased from 10 in week 30, 2022 to 13 cases. These were reported from Ondo, Edo, Kogi, Ebonyi, and Imo states.

“Cumulatively from week 1 to week 31, 2022, 165 deaths have been reported with a case fatality rate (CFR) of 18.8 per cent which is lower than the CFR for the same period in 2021 (23.1 per cent).

“In total for 2022, 25 States have recorded at least one confirmed case across 100 Local Government Areas.

“Of all confirmed cases, 70 per cent are from Ondo (31 per cent), Edo (26 per cent), and Bauchi (13 per cent) states.”

The NCDC stated that the predominant age group affected were 21-30 years, Range from zero to 90 years, Median Age: 30 years).

It said that the male-to-female ratio for confirmed cases was 1:0.8.

“The number of suspected cases has increased compared to that reported for the same period in 2021.

“No new healthcare worker affected in the reporting week 31,” it said.

The NCDC, however, said that the National Lassa fever multi-partner, multi-sectoral Technical Working Group (TWG) had continued to coordinate the response activities at all levels.

Continue Reading

Trending